[1]徐娜,综述,袁晋青,等.高龄非血运重建急性冠状动脉综合征患者的抗血小板治疗进展[J].心血管病学进展,2016,(2):108-111.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.003]
　XU Na,YUAN Jinqing.Progress of Antiplatelet Therapy in Senior Patients with Acute Coronary Syndrome without Revascularization[J].Advances in Cardiovascular Diseases,2016,(2):108-111.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.003]
点击复制

高龄非血运重建急性冠状动脉综合征患者的抗血小板治疗进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年2期
页码:
108-111
栏目:
主题综述
出版日期:
2016-04-20

文章信息/Info

Title:
Progress of Antiplatelet Therapy in Senior Patients with Acute Coronary Syndrome without Revascularization
作者:
徐娜; 综述; 袁晋青; 审校
北京协和医学院 中国医学科学院 北京阜外心血管病医院心内科,北京 100037
Author(s):
XU Na; YUAN Jinqing
Fuwai Hospital and Cardiovascular Institute,National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
关键词:
高龄;  非血运重建;  急性冠状动脉综合征;  抗血小板
Keywords:
Senior;  Without revascularization;  Acute coronary syndrome;  Antiplatelet
分类号:
R541.4; R972
DOI:
10.16806/j.cnki.issn.1004-3934.2016.02.003
文献标志码:
A
摘要:
急性冠状动脉综合征在老年人群中具有较高发病率且是其主要死亡原因之一。高龄急性冠状动脉综合征患者常合并多种疾病,病情复杂,接受血运重建的比率低,且非血运重建患者中药物治疗不充分。高龄非血运重建急性冠状动脉综合征患者的抗血小板治疗具有更高出血风险,其抗血小板治疗的临床获益与风险需要进行权衡。现就高龄非血运重建急性冠状动脉综合征患者的抗血小板治疗进展予以综述,以期为临床医生决策提供依据和参考。
Abstract:
Acute coronary syndrome(ACS)has a high incidence rate and is one of the major causes of death in the senior population.Senior patients often have complications from other diseases, and their conditions are complex and the rate of revascularization and drug treatment is low.Senior patients without revascularization of ACS have a higher risk of bleeding and due to this, the clinical benefit and risk of antiplatelet therapy should be weighed.We reviewed the progress of antiplatelet therapy in senior patients without revascularization of ACS in order to provide the basis and reference for clinical doctors.

参考文献/References:

[1] Andreotti F, Rocca B, Husted S, et al.Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardology Working Group on Thrombosis[J].Eur Heart J,2015,36(46):3238-3249.
[2] Lopes RD, Alexander KP.Antiplatelet therapy in older adults with non-ST-segment elevation acute coronary syndrome: considering risks and benefits[J].Am J Cardiol,2009,104:16C-21C.
[3] Amsterdam EA,Wenger NK,Brindis RG, et al.2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2014,64(24):e139-228.
[4] Fox KA, Anderson FA Jr, Dabbous OH, et al.Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events(GRACE)[J].Heart,2007,93(2):177-182.
[5] Bi Y, Gao R, Patel A,et al.Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China(CPACS)study[J].Am Heart J,2009,157(3):509-516.
[6] Buber J, Goldenberg I, Kimron L,et al.One-year outcome following coronary angiography in elderly patients with non-ST elevation myocardial infarction: real-world data from the Acute Coronary Syndromes Israeli Survey(ACSIS)[J].Coron Artery Dis,2013,24(2):102-109.
[7] Li YQ, Liu N, Lu JH.Outcomes in patients with non-ST-elevation acute coronary syndrome randomly assigned to invasive versus conservative treatment strategies: a meta analysis[J].Clinics(Sao Paulo),2014,69(6):398-404.
[8] de Carlo M, Morici N, Savonitto S, et al.Sex-related outcomes in elderly patient presenting with non-ST-segment elevation acute coronary syndrome: insights from the Italian Elderly ACS Study[J].JACC Cardiovasc Interv,2015,8(6):791-796.
[9] Gale CP, Cattle BA, Woolston A, et al.Resolving inequalities in care? Reduced mortality in the elderly after acute coronary syndromes.The Myocardial Ischaemia National Audit Project 2003-2010[J].Eur Heart J,2012,33(5):630-639.
[10] Rhee JW, Wiviott SD, Scirica BM, et al.Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome[J].Clin Cardiol,2014,37(6):350-356.
[11] Fischer MJ, Ho PM, McDermott K, et al.Chronic kidney disease is associated with adverse outcomes among elderly patients taking clopidogrel after hospitalization for acute coronary syndrome[J].BMC Nephrol,2013,14:107.
[12] Liu Y, Gao L, Xue Q,et al.Impact of renal dysfunction on long-term outcomes of elderly patients with acute coronary syndrome: a longitudinal, prospective observational study[J].BMC Nephrol,2014,15:78.
[13] Wiviott SD, Steg PG.Clinical evidence for oral antiplatelet therapy in acute coronary syndromes[J].Lancet,2015,336(9990):292-302.
[14] Roe MT, Armstrong PW, Fox KA, et al.Prasugrel versus clopidogrel for acute coronary syndromes without revascularization[J].N Engl J Med, 2012,367(14):1297-1309.
[15] Roe MT, Goodman SG, Ohman EM,et al.Elderly patients with acute coronary syndromes managed without revascularization:insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel[J].Circulation,2013,128:823-833.
[16] Montalescot G, van't Hof AW, Lapostolle F,et al.Prehospital ticagrelor in ST-segment elevation myocardial infarction[J].N Engl J Med, 2014,371(11):1016-1027.
[17] Husted S, James S, Becker RC, et al.Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes:a substudy from the prospective randomized Platelet Inhibition and Patient Outcomes(PLATO)trial[J].Circ Cardiovasc Qual Outcomes,2012,5:680-688.
[18] Montalescot G, Bolognese L, Dudek D,et al.Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes[J].N Engl J Med,2013,369(11):999-1010.
[19] 急性冠状动脉综合征非血运重建患者抗血小板治疗中国专家共识组.急性冠状动脉综合征非血运重建患者抗血小板治疗的中国专家共识[J].中华内科杂志,2009,48:9.
[20] Wiviott SD, White HD, Ohman EM, et al.Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial[J].Lancet,2013,382(9892):605-613.

相似文献/References:

[1]林莹 徐勇郭新红 刘昱圻.具有不同肌酐清除率水平的中国高龄非瓣膜性心房颤动患者应用利伐沙班的剂量选择研究[J].心血管病学进展,2019,(8):1176.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.027]
　LIN Ying,XU Yong,GUO Xinhong,et al.Dose Selection of Rivaroxaban for Elderly Patients of Non-valvular Atrial Fibrillation with Different Levels of Creatinine Clearance in China[J].Advances in Cardiovascular Diseases,2019,(2):1176.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.027]
[2]安子玉 梁颖慧 秦明照.高龄高血压患者降压治疗的相关问题[J].心血管病学进展,2021,(3):236.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.011]
　AN Ziyu,LIANG Yinghui,QIN Mingzhao.Antihypertensive Treatment in Very Elderly Patients with Hypertension[J].Advances in Cardiovascular Diseases,2021,(2):236.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.011]

备注/Memo

备注/Memo:
基金项目:“十二五”国家科技支撑计划项目(2011BAI11B07); 国家自然科学基金(81470486) 作者简介:徐娜(1992—),住院医师,在读硕士,主要从事冠心病研究。Email: 1060768475@qq.com 通信作者:袁晋青(1962—),教授,主任医师,博士,主要从事冠心病研究。Email: jqyuan29007@sina.com
更新日期/Last Update: 2016-03-25